Investors Sell Johnson & Johnson (JNJ) on Strength (JNJ)

Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Thursday. $180.78 million flowed into the stock on the tick-up and $276.60 million flowed out of the stock on the tick-down, for a money net flow of $95.82 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 4th highest net out-flow for the day. Johnson & Johnson traded up $0.04 for the day and closed at $139.50

JNJ has been the subject of a number of recent analyst reports. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Friday, July 13th. Goldman Sachs Group upgraded shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a report on Friday, September 14th. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Finally, Sanford C. Bernstein initiated coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 target price for the company. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $144.25.

The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $370.70 billion, a PE ratio of 19.00, a P/E/G ratio of 2.19 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. During the same period in the previous year, the firm earned $1.90 earnings per share. Johnson & Johnson’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Shareholders of record on Tuesday, November 27th will be paid a dividend of $0.90 per share. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.58%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

In other Johnson & Johnson news, COO Michael E. Sneed sold 29,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the business’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Phocas Financial Corp. grew its stake in Johnson & Johnson by 999,927.7% during the second quarter. Phocas Financial Corp. now owns 129,463,583 shares of the company’s stock worth $1,571,000 after buying an additional 129,450,637 shares during the period. Glenmede Trust Co. NA lifted its position in shares of Johnson & Johnson by 149.8% during the second quarter. Glenmede Trust Co. NA now owns 22,174,682 shares of the company’s stock worth $2,690,676,000 after purchasing an additional 13,295,992 shares in the last quarter. BlackRock Inc. lifted its position in shares of Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after purchasing an additional 7,853,141 shares in the last quarter. Boston Partners lifted its position in shares of Johnson & Johnson by 68.7% during the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after purchasing an additional 5,207,124 shares in the last quarter. Finally, Fundsmith Equity Fund L.P. acquired a new position in shares of Johnson & Johnson during the second quarter worth $552,762,000. Institutional investors own 66.67% of the company’s stock.

About Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Earnings Per Share

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply